. 2019 Nov 24;20(23):5890. doi: 10.3390/ijms20235890

Table 1.

The relative stability of flavonol aglycones in four digestive conditions in vitro.

Compound	Digestive Conditions
Compound	Control	Gastric	Pancreatin	BBMV ^a	Pancreatin + BBMV ^b
Kaempferol	99.20 ± 4.30 ^Ac	93.40 ± 2.60 ^A	65.50 ± 0.50 ^BC	72.23 ± 0.63 ^B	54.97 ± 0.58 ^C
Myricetin	101.60 ± 1.53 ^A	98.97 ± 2.36 ^A	n.d. ^d	n.d.	n.d.
Quercetin	99.07 ± 5.48 ^A	96.47 ± 1.35 ^A	9.23 ± 0.35 ^B	4.47 ± 0.12 ^C	n.d.

^a BBMV: brush border membrane vesicle. ^b Pancreatin + BBMV: co-treatment with pancreatin and BBMV. ^c Data are expressed as a percentage (%) compared with control in each condition. Data with different uppercase letters in the same row represent significant differences according to the Tukey–Kramer honest significant difference test (p < 0.05) with standard error of the mean. ^d n.d. means not detected.